博晖创新(300318) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥252,950,995.14, representing a 44.22% increase compared to ¥175,394,242.89 in the same period last year[5] - Net profit attributable to shareholders was ¥5,174,206.08, a significant turnaround from a loss of ¥13,243,101.60 in Q1 2022, marking a 139.07% increase[5] - Basic earnings per share rose to ¥0.0063 from a loss of ¥0.0162, indicating a 138.89% improvement[5] - Total operating revenue for Q1 2023 was CNY 252,950,995.14, an increase of 44.4% compared to CNY 175,394,242.89 in Q1 2022[28] - Net profit for Q1 2023 reached CNY 9,672,620.16, a significant recovery from a net loss of CNY 26,680,596.65 in Q1 2022[29] - The company reported a gross profit margin of approximately 4.9% for Q1 2023, compared to a negative margin in Q1 2022[29] - The total comprehensive income for the first quarter of 2023 was CNY 9,156,153.67, compared to a loss of CNY 26,934,387.20 in the same period last year[30] Cash Flow and Financial Position - The net cash flow from operating activities improved to ¥5,173,217.62, compared to a negative cash flow of ¥29,404,292.88 in the previous year, reflecting a 117.59% increase[5] - The company reported a decrease in cash and cash equivalents to ¥93,007,540.49 from ¥113,600,046.91 at the beginning of the year, representing a decline of approximately 18.3%[22] - The company’s cash and cash equivalents were CNY 1,103,368,335.50, down from CNY 1,140,130,256.34 in the previous year[24] - The net cash flow from financing activities was CNY 39,680,216.45, a decrease from CNY 132,357,092.92 in the previous year[34] - The company incurred cash outflows from investing activities totaling CNY 65,391,879.04, compared to CNY 37,529,195.84 in the same period last year[34] - The company received CNY 311,022,700.66 in cash from borrowings, significantly higher than CNY 68,000,000.00 in the previous year[34] - The total cash inflow from financing activities was CNY 693,022,700.66, compared to CNY 237,100,000.00 in the same period last year[34] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,883,039,678.80, a slight decrease of 0.64% from ¥3,908,002,277.01 at the end of the previous year[5] - Total liabilities decreased to CNY 1,550,004,592.03 in Q1 2023 from CNY 1,584,123,343.91 in Q1 2022[25] - The company’s equity attributable to shareholders increased to CNY 1,398,188,443.27 from CNY 1,393,532,991.70 year-over-year[26] Operational Highlights - The company experienced a 40.62% increase in cash received from sales, totaling ¥258,419,243.49, driven by growth in blood product sales[12] - The company reported a 715.48% increase in other income, amounting to ¥1,781,470.44, primarily due to increased government subsidies received[10] - The company’s financial expenses decreased by 50.34% to ¥6,238,699.81, attributed to a reduction in short-term debt[10] - Revenue from sales of goods and services received cash of CNY 258,419,243.49, up from CNY 183,767,004.44 in the prior year[32] Shareholder Information - Major shareholder Du Jiangtao holds 39.03% of the shares, totaling 318,811,388 shares[15] - The company has a total of 20,001,720 shares under lock-up, with 178,500 shares released during the period[18] - The company’s vice president reduced her holdings by 179,000 shares at an average price of ¥6.1128 per share, accounting for 0.0219% of the total share capital[19] Investments and Development - The company’s cash outflow for the purchase of fixed assets increased by 74.43% to ¥65,391,879.04, reflecting ongoing investments in the Yunnan blood product project[12] - The company provided guarantees totaling up to ¥650 million for its subsidiaries, with ¥250 million specifically allocated for financing through a cloud platform[20] - The company’s subsidiary obtained a single plasma collection license from the Yunnan Provincial Health Commission[20] - Research and development expenses for Q1 2023 were CNY 14,197,200.03, slightly up from CNY 13,783,836.86 in Q1 2022[29] Receivables and Inventory - Accounts receivable decreased to ¥65,251,577.57 from ¥75,921,242.82, a reduction of about 13.9%[23] - Inventory slightly decreased to ¥860,199,805.87 from ¥870,516,782.75, indicating a decrease of approximately 1.4%[23] - The company’s total receivables from financing decreased to ¥3,120,031.32 from ¥6,485,146.87, a decline of approximately 51.8%[23] - The company’s prepayments increased to ¥15,106,599.30 from ¥8,255,312.80, reflecting an increase of about 83.3%[23]